UCLouvain

Running trials

• Not yet recruiting

  The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment

  NCT07788573· Source

• Recruiting

  CKD Cachexia and Gut Microbiome

  NCT06986265· Source

• Active, not recruiting

  A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

  NCT06356311· PHASE3· Source

• Recruiting

  CAP48 - Autism in Children and Adolescents

  NCT06149468· Source

• Recruiting

  Flexible Reaching Control in Parkinson Disease

  NCT05908266· Source

• Recruiting

  Gait Control in Parkinson Disease

  NCT05908279· Source

• Active, not recruiting

  Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

  NCT03924895· PHASE3· Source

• Active, not recruiting

  An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS

  2023-507906-15-00· PHASE3· Source

• Recruiting

  Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates

  NCT05276037· Source

• Recruiting

  GRAALL2014

  NCT02617004· PHASE2· Source

• Recruiting

  Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults

  NCT07000916· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Parkinson disease2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Autism1 recruiting
• Chronic kidney disease1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lupus (SLE)1 recruiting
• Multiple sclerosis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A PHASE 1/2 STUDY OF ONCOBAX®-AK ADMINISTERED IN COMBINATION WITH IMMUNOTHERAPY TO PATIENTS WITH ADVANCED SOLID TUMORS

  2024-516711-24-00· PHASE1 PHASE2· Source

Trial sites

• UCLouvain3 trials
• Université Catholique de Louvain1 trial
• Catholic University of Louvain1 trial
• Université catholique de Louvain2 trials
• Universite Catholique de Louvain5 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Haemophilia40 works · 0 trials
• Polycystic kidney disease11 works · 0 trials